Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Mumbai: 32-Year-Old Dies In Kandivali After Scooter Crash During WhatsApp Video Call
EPFO 2025 Update, Government Launches New Employee Enrollment Scheme — A Second Chance for Workers
Andhra Pradesh: YSRCP President Jagan Mohan Reddy Slams CM Chandrababu Naidu’s ‘Feudal-Era Boasting’, Says Cyclone Management Was PR, Not Real Governance
Kashmir Marathon 2.0: Chief Minister Omar Abdullah, Bollywood Actor Suniel Shetty Jointly Flag Off Race In Srinagar - VIDEO
